

"Rheum to Diagnosis": Uncovering Impediments to Accurate Diagnosis of Non-radiographic Axial Spondyloarthritis

BACKGROUND

- In the US, there is up to a 14-year delay in axSpA diagnosis
- Timely detection of patients with nr-axSpA remains a major obstacle to appropriate care
- Impediments to timely diagnosis of nr-axSpA are inadequately understood
- This study aimed to characterize the journey to nr-axSpA diagnosis and factors contributing to diagnostic delay

OBJECTIVES

Primary

• To determine the impediments to diagnosis of nr-axSpA in the US

Secondary

- To determine the top 5 types of HCPs seen by patients before nr-axSpA diagnosis
- To determine the number of rheumatologists seen before nr-axSpA diagnosis

Exploratory

• To investigate if demographic factors determine delay in diagnosis

METHODS

- Mixed-methods study (Figure 1)
- Qualitative component (February 2020)
- Convenience sampling method
- 15 rheumatologists and 25 patients
- Semistructured phone interviews
- Grounded theory analytical approach
- Quantitative component (April-July 2020)
- Overarching qualitative themes integrated into online, self-administered survey and subsequent analysis

Figure 1. Mixed-Methods Study




Table 1. Qualit

Recruitme Screen Quali Interviewed

Table 2. Quan

Respond

Ineligi

Analy

cludes respondents v unreliable surveys (gamers, flatliners, and surveys with implausible responses [n=247])

RESULTS

Qualitative Phase Results

Quantitative Phase Results

- 51% saw ≥4 different HCPs before rheumatologist (**Figure 4**)
- 47% saw \geq 2 rheumatologists before nr-axSpA diagnosis (**Figure 4**)
- Interval from symptom onset to nr-axSpA diagnosis: ≤ 2 years (49%) to ≥ 11 years (23%) (**Figure 5**)
- Issues perceived as leading barriers to timely diagnosis (Table 4)
- Symptoms are a consequence of activity or age
- HCPs minimize, overlook, or misinterpret signs of inflammatory disease
- Missed diagnoses due to young age, female sex


S Kiwalkar,¹ R Howard,² A Deodhar¹

¹Oregon Health & Science University, Portland, Oregon; ²Spondylitis Association of America, Van Nuys, California

ative Interviews Sample							
	Patients	Patients	Rheumatologists				
nt	SAA monthly newsletter	Back pain panel	SAA list				
d	165	1425	26				
d	50	15					
d	24	1	15				

itative Patient Interviews Sample						
	Total	SAA sample	General sample			
ed	16,283	252	16,031			
e ^a	16,097	164	15,933			
ed	186	88	98			
o did not meet criteria for rheumatology-confirmed nr-axSpA (n=15,702), incomplete surveys (n=148), and						

• Patients recruited via SAA newsletter, social media channels, and back pain patient databases, and screened for eligibility.







Table 3. Demographic Characteristics				
Sex Female				
Male				
Mean age (range), years				
Race/ethnicity				
Asian				
Black				
LatinX				
White				
Multiracial				
Other				
Education				
High school or less				
Trade/technical school				
Some college or associate degree				
Bachelors degree Advanced degree				
Work status (prior to pandemic) Student				
Full time				
Part time				
Stay-at-home parent				
Retired				
On disability				

Unemployed

Figure 4. Interactions With HCPs Prior to nr-axSpA Diagnosis^a



Percentages may not total 100 due to rounding.





Figure 5. Time From Symptom Onset to nr-axSpA Diagnosis^a



^a Data missing for 1% of respondents

	Table 4. Translation of Qualitative Themes to Quantitative Res				
	Themes from qualitative interviews Patients (n=25) and rheumatologists (n=15)	Quantitative survey findir Patients (n=186)			
	Patients feel back pain is normal or age related and does not require prompt medical care	64%: joint pains due to act 29%: pain due to aging 23%: symptoms are growito to young age			
	Clinicians often minimize persistent symptoms, especially if they occur in young and/or female patients	38%: HCP thought sympto my head" 25%: told nr-axSpA is a "n [<i>female respondents only</i>]			
	Physicians, including rheumatologists, do not know enough about nr-axSpA or inflammatory back disease	53%: HCPs attributed sym activity or injury 25%: initially misdiagnosed			
	Specific biomarkers to facilitate diagnosis are currently lacking	36%: normal x-rays or MR 38%: negative HLA-B27 st contributed to delayed dia [<i>HLA-B27–negative resport</i>]			
	Delayed referral to rheumatologist	32%: medical professional know to refer to rheumatol 25%: limited access to rhe 11%: requested referral to rheumatologist but denied			
r	Seeing a rheumatologist does not necessarily lead to a prompt diagnosis	 48%: saw ≥2 rheumatolog nr-axSpA diagnosis 22%: received conflicting of from rheumatologists 			

16%: rheumatologists were unaware of nr-axSpA

ctivity or injury

ing pains due

toms were "in

'man's disease"

mptoms to

RI were barriers

status iagnosis ndents only] als did not logist

eumatologists

gists before

diagnoses

CONCLUSIONS

- Both patients and clinicians may be unfamiliar with IBP and nraxSpA and may not realize that nr-axSpA can occur in young people and females and that patients with nr-axSpA can have normal x-rays
- Patients with nr-axSpA often see multiple HCPs before receiving diagnosis
- Disease recognition by non-rheumatology HCPs is key for early referral
- Education on cardinal features, epidemiology, burden, and benefits of timely nr-axSpA diagnosis is warranted for HCPs who commonly manage back pain

LIMITATIONS

 SAA-derived participants may be more knowledgeable about this condition and thus not representative of the general public

REFERENCES

1. Deodhar A, et al. Arthritis Rheumatol. 2016;68:1669-1676.

DISCLOSURES

Kiwalkar: Nothing to disclose

Howard: Consulting/advisory board: Novartis

Stock: AbbVie, Amgen, Bristol Myers Squibb, GSK, Johnson & Johnson, Lilly, Merck, Novartis, Pfizer. Teva

Deodhar: Consulting/advisory boards: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, GSK, Janssen, Novartis, Pfizer, UCB Research Grants: AbbVie, Lilly, GSK, Novartis, Pfizer, UCB

Study funding provided by UCB.

ABBREVIATIONS

ASAS, Assessment in SpondyloArthritis international Society; Endo, endocrinologist; GI, gastroenterologist; HCP, healthcare provider; IBD, inflammatory bowel disease; IBP, inflammatory back pain; MRI, magnetic resonance imaging scan; NP, nurse practitioner; NSAID, nonsteroidal anti-inflammatory drug; Ophth, ophthalmologist; Pain, pain specialist; PCP, primary care physician; PM&R, physical medicine and rehabilitation specialist; PT, physical therapist; RA, rheumatoid arthritis; SAA, Spondylitis Association of America; Spine, spine specialist Sports, sports medicine specialist.



OREGON HEALTH&SCIENCE JNIVERSITY